Are we worried enough about selective serotonin receptor inhibitors and upper gastrointestinal bleeding?

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 1, 2015, Pages 51-54

  Targownik, Laura E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; CASE CONTROL STUDY; COHORT ANALYSIS; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EDITORIAL; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; METHODOLOGY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH PROTECTION; THROMBOCYTE AGGREGATION INHIBITION; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED; GASTROINTESTINAL HEMORRHAGE;

GASTROINTESTINAL HEMORRHAGE; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84916910359     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.032     Document Type: Editorial

References (33)

1. Mann J.J. The medical management of depression. NEngl J Med 2005, 353:1819-1834.
2. Baldwin D., Woods R., Lawson R., et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011, 342:d1199.
3. Stein D.J., Koen N., Fineberg N., et al. A2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep 2012, 14:211-219.
4. Vieta E., Locklear J., Gunther O., et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. JClin Psychopharmacol 2010, 30:579-590.
5. Hauser W., Urrutia G., Tort S., et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013, 1:CD010292.
6. Bundeff A.W., Woodis C.B. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother 2014, 48:777-784.
7. Landy S., McGinnis J., Curlin D., et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999, 39:28-32.
8. McKenzie M.S., McFarland B.H. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf 2007, 16:513-523.
9. Andrade C., Sandarsh S., Chethan K.B., et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. JClin Psychiatry 2010, 71:1565-1575.
10. Targownik L.E., Bolton J.M., Metge C.J., et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009, 104:1475-1482.
11. de Abajo F.J., Garcia-Rodriguez L.A. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008, 65:795-803.
12. de Abajo F.J., Rodriguez L.A., Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999, 319:1106-1109.
13. Dalton S.O., Johansen C., Mellemkjaer L., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003, 163:59-64.
14. Tata L.J., Fortun P.J., Hubbard R.B., et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?. Aliment Pharmacol Ther 2005, 22:175-181.
15. Wessinger S., Kaplan M., Choi L., et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006, 23:937-944.
16. Helin-Salmivaara A., Huttunen T., Gronroos J.M., et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol 2007, 63:403-408.
17. Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009, 29:481-496.
18. Lanza F.L., Chan F.K., Quigley E.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
19. Dall M., dePont Christensen R., Schaffalitzky de Muckadell O.B., et al. Re-prescribing of causative drugs in persons discharged after serious drug-induced upper gastrointestinal bleeding. Aliment Pharmacol Ther 2012, 35:948-954.
20. Jiang H.Y., Chen H.Z., Hu X.J., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015, 13:42-50.
21. Anglin R., Yuan Y., Moayyedi P., et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014, 109:811-819.
22. Masclee G.M., Valkhoff V.E., Coloma P.M., et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014, 147:784-792.
23. Edwards I.R. Considerations on causality in pharmacovigilance. Int J Risk Saf Med 2012, 24:41-54.
24. Swaen G., van Amelsvoort L. Aweight of evidence approach to causal inference. JClin Epidemiol 2009, 62:270-277.
25. Bismuth-Evenzal Y., Gonopolsky Y., Gurwitz D., et al. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. JAffect Disord 2012, 136:99-103.
26. Maurer-Spurej E., Pittendreigh C., Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004, 91:119-128.
27. Shin D., Oh Y.H., Eom C.S., et al. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. JNeurol 2014, 261:686-695.
28. Auerbach A.D., Vittinghoff E., Maselli J., et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013, 173:1075-1081.
29. Palmsten K., Hernandez-Diaz S., Huybrechts K.F., et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013, 347:f4877.
30. Dall M., Schaffalitzky de Muckadell O.B., Moller Hansen J., et al. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scand J Gastroenterol 2011, 46:1039-1044.
31. Fogarty C.T., Sharma S., Chetty V.K., et al. Mental health conditions are associated with increased health care utilization among urban family medicine patients. JAm Board Fam Med 2008, 21:398-407.
32. McLaughlin T.P., Khandker R.K., Kruzikas D.T., et al. Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization. JClin Psychiatry 2006, 67:1187-1193.
33. Koloski N.A., Talley N.J., Boyce P.M. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 2001, 96:1340-1349.